22. Moyamoya disease Clinical trials / Disease details

Clinical trials : 17 / Drugs : 22 - (DrugBank : 17) / Drug target genes : 33 - Drug target pathways : 45

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-jRCTs071220048	29/08/2022	29/08/2022	Angiogenesis augmentation therapy for indirect revascularization of moyamoya disease using G-CSF	Angiogenesis augmentation therapy for indirect revascularization of moyamoya disease using G-CSF - EDFAPS-G	Moyamoya disease Moyamoya disease, indirect revascularization, Granulocyte-Colony Stimulating Factor;D009072	G-CSF(75 micrograms/body) is applied intraoperatively to the indirect revascularization site, and G-CSF (75 micrograms/body) is given intravenously once daily for 2 days.	Morioka Motohiro	NULL	Recruiting	>= 20age old	<= 60age old	Both	5	Phase 1-2	Japan
2	ChiCTR2100050185	2021-08-23	2021-08-21	Effect of stellate ganglion block on intracranial vascular and prognosis in patients with Moyamoya disease	Effect of stellate ganglion block on intracranial vascular and prognosis in patients with Moyamoya disease	Moyamoya disease	SGB group:Ipsilateral stellate ganglion block was performed with 0.2% ropivacaine 8ml;control group:Routine extracranial artery bypass grafting only;	The First Affiliated Hospital of Sun Yat-sen University	NULL	Pending	12	65	Both	SGB group:12;control group:12;	Phase 1	China
3	ChiCTR2100050015	2021-08-12	2021-08-15	Effect of stellate ganglion block on intracranial vascular and stress level in patients with Moyamoya disease	Effect of stellate ganglion block on intracranial vascular and stress level in patients with Moyamoya disease	Moyamoya disease	stellate ganglion group:1.5% lidocaine planetary ganglion block; control group:DSA only, no stellate ganglion block;	the First Affiliated Hospital of Sun Yat-Sen University	NULL	Pending	12	65	Both	stellate ganglion group:12; control group:12;		China
4	ChiCTR2100046178	2021-05-10	2021-05-08	Efficacy and safety of antiplatelet drugs in patients with moyamoya disease after revascularization	Efficacy and safety of antiplatelet drugs in patients with moyamoya disease after revascularization	Moyamoya disease	Taking aspirin group:Nil;No aspirin group:Nil;	Qilu Hospital of Shandong University	NULL	Recruiting	0	60	Both	Taking aspirin group:105;No aspirin group:105;		china
5	JPRN-jRCTs031200402	23/04/2021	08/03/2021	Search for abnormalities of fundus blood vessels in moyamoya disease	Search for abnormalities of fundus blood vessels in moyamoya disease	Moyamoya disease Moyamoya disease	For fluorescein fundus angiography, 500 mg of fluorescein (5 ml vial of aqueous solution containing 500 mg of fluorescein) and 25 mg of Ophthagreen (2 ml of blue indocyanine green) are dissolved in 2 ml of distilled water for injection and injected through the forearm of the elbow vein. In daily practice, diabetic retinopathy can be treated by using a diabetic retinal imaging system (optos). In daily practice, it is used for the diagnosis of diabetic retinopathy, uveitis, occlusive retinal vascular disease, and age-related macular degeneration.	Akiyama Hideo	NULL	Recruiting	>= 20age old	Not applicable	Both	50	N/A	Japan
6	ChiCTR2000041260	2021-01-01	2020-12-23	The effects of norepinephrine and phenylephrine on cerebral oxygenation in treating intraoperative hypotension in STA-MCA bypass surgery	The effects of norepinephrine and phenylephrine on cerebral oxygenation in treating intraoperative hypotension in STA-MCA bypass surgery	moyamoya disease	Group 1:iv norepinephrine;Group 2:iv phenylephrine;	The South District of Anhui Provincial Hospital	NULL	Recruiting	18	65	Both	Group 1:30;Group 2:30;	Phase 4	China
7	ChiCTR2000029878	2020-11-01	2020-02-16	The effects of norepinephrine and phenylephrine on cerebral oxygenation in treating intraoperative hypotension in STA-MCA bypass surgery	The effects of norepinephrine and phenylephrine on cerebral oxygenation in treating intraoperative hypotension in STA-MCA bypass surgery	moyamoya disease	Group 1:iv norepinephrine;Group 2:iv phenylephrine;	The South District of Anhui Provincial Hospital	NULL	Pending	18	65	Both	Group 1:30;Group 2:30;	Phase 4	China
8	NCT04205578 (ClinicalTrials.gov)	January 2020	18/12/2019	NBP in Patients With Moyamoya Disease of High Risk for Ischemic Cerebrovascular Events	A Multi-center, Randomized, Single-blind, Placebo-controlled Study of Dl-3-n-butylphthalide in Patients With Moyamoya Disease of High Risk for Ischemic Cerebrovascular Events After Extracranial-to-intracranial Revascularization Surgery	Moyamoya Disease;Ischemic Cerebral Infarction;Ischemic Stroke;Ischemic Cerebrovascular Accident;Transient Ischemic Attack	Drug: dl-3-n-butylphthalide (NBP);Drug: Normal Saline 0.9% Infusion Solution	yuanli Zhao	Peking University International Hospital	Not yet recruiting	18 Years	60 Years	All	450	Phase 3	China
9	NCT04012268 (ClinicalTrials.gov)	July 15, 2019	3/7/2019	The Safety and Efficacy of RIC on Adult Moyamoya Disease	The Safety and Effect of Remote Ischemic Conditioning on Adult Moyamoya Disease	Moyamoya Disease	Device: RIC;Drug: Aspirin	Capital Medical University	NULL	Completed	18 Years	60 Years	All	30	N/A	China
10	ChiCTR1900027197	2019-05-01	2019-11-04	Study on the protective effect of desflurane combined with propofol on the brain of patients with moyamoya disease undergoing cerebral revascularization	Study for the protective effect of desflurane on the brain of patients with moyamoya disease	Moyamoya disease	Group D:Desflurane for anesthesia maintenance;GroupP:Propofol;GroupPD:Desflurane and propofol;	The First Affiliated Hospital of Zhengzhou University	NULL	Completed	20	65	Both	Group D:30;GroupP:30;GroupPD:30;	Phase 4	China
11	NCT03882060 (ClinicalTrials.gov)	April 8, 2019	12/3/2019	Effect of Recombinant Human EPO on the Postoperative Neurologic Outcome in Pediatric Moyamoya Patients	The Effect of Recombinant Human Erythropoietin on the Postoperative Neurologic Outcome in Pediatric Moyamoya Disease Patients - A Double Blind Randomized Controlled Trial	Moyamoya Disease;Pediatrics;Cerebrovascular Disorders	Drug: erythropoietin;Drug: Normal saline	Seoul National University Hospital	NULL	Active, not recruiting	N/A	18 Years	All	60	N/A	Korea, Republic of
12	ChiCTR1800020377	2019-01-01	2018-12-27	Aspirin in Moyamoya Disease	The Clinical Benefit and Risk of Oral Aspirin for Moyamoya Disease	moyamoya disease	Case series:Aspirin;	Beijing Tiantan Hospital, Capital Medical University	NULL	Recruiting	8	60	Both	Case series:300;		China
13	JPRN-jRCTs031180017	01/08/2018	07/09/2018	Studies on the utility of simultaneous-multi-slice acquisition (SMS) dynamic susceptibility contrast-enhanced (DSC)MRI for the occulusive cerebrobascular disease	Studies on the utility of simultaneous-multi-slice acquisition (SMS) dynamic susceptibility contrast-enhanced (DSC)MRI for the occulusive cerebrobascular disease - SMS DSC-MRI study for the occulusive cerebrobascular disease	carotid artery stenosis, moyamoya disease	Intravenous administration of gadobutrol (Gadovist, Bayer Schering Pharma, Berlin, Germany) is administered in the supine position, and high speed DSC-MRI scan by using SMS acquisition (temporal resolution of 0.5s) is carried out at the same time as injection of the contrast agent with an acquisition time of 70sec. The quantitative and qualitative comparison between reference data set (0.5s) and additional data sets with temporal resolution of 1.0s, 1.5s, and 2.0s generated from the reference data set, is performed.	Aoki Shigeki	Bayer Yakuhin, Ltd;Bayer Yakuhin, Ltd	Complete	>= 20age old	Not applicable	Both	50	N/A	Japan
14	NCT02510586 (ClinicalTrials.gov)	August 2015	24/7/2015	Sevoflurane and Hyperperfusion Syndrome	Effect of Sevoflurane-induced Postconditioning on the Incidence of Postoperative Cerebral Hyperperfusion Syndrome After Revascularization Surgery in Adult Patients With Moyamoya Disease	Hyperperfusion Syndrome;Moyamoya Disease	Drug: Sevoflurane	Seoul National University Hospital	NULL	Not yet recruiting	18 Years	N/A	Both	152	N/A	NULL
15	JPRN-UMIN000008742	2012/09/01	21/08/2012	Studies on the effect of free radical scavenger Edaravone against postoperative hyper-perfusion syndrome after STA-MCA bypass surgery for adult moyamoya disease.	Studies on the effect of free radical scavenger Edaravone against postoperative hyper-perfusion syndrome after STA-MCA bypass surgery for adult moyamoya disease. - Studies on the effect of free radical scavenger Edaravone against postoperative hyper-perfusion syndrome after STA-MCA bypass surgery for adult moyamoya disease.	moyamoya disease	Administration of edaravone from preoperative to postoperative day 7.	Department of Neurosurgery, Hokkaido University Graduate School of Medicine	NULL	Complete: follow-up complete	16years-old	Not applicable	Male and Female	32	Not applicable	Japan
16	NCT03162588 (ClinicalTrials.gov)	May 1, 2010	18/5/2017	Multiple Burrhole Therapy With Erythropoietin for Unstable Moyamoya	Feasibility Study of Multiple Burrhole Therapy Combined With Intravenous Erythropoietin Pretreatment for Unstable Moyamoya	Ischemic Attack;Ischemic Stroke;Moyamoya Disease;Burr Hole;Angiogenesis	Drug: erythropoietin	Ajou University School of Medicine	NULL	Completed	16 Years	N/A	All	37	Phase 1/Phase 2	Korea, Republic of
17	NCT01419275 (ClinicalTrials.gov)	April 2009	16/8/2011	Quantifying Collateral Perfusion in Cerebrovascular Disease-Moyamoya Disease and Stroke Patients	Quantifying Collateral Perfusion in Cerebrovascular Disease-Moyamoya Disease and Stroke Patients	Cerebrovascular Accident;Moyamoya Disease	Drug: Xenon contrast agent;Device: Magnetic Resonance Imaging	Stanford University	NULL	Completed	N/A	N/A	All	126	N/A	United States